Ocular drug delivery is not a single formulation problem. It is a system design problem created by the layered anatomy of the eye, rapid clearance
Protein formulation development is not a buffer recipe exercise. It is the design of a complete product system that has to preserve molecular structure, biological
Selecting the right solubility enhancement strategies is one of the earliest formulation decisions for a poorly soluble drug candidate. Low solubility can limit the amount
The Challenge: Treating Meibomian Gland Dysfunction in Dry Eye Disease Dry eye disease is a multi-parametric disorder of the tear fluid and ocular surface that
The Challenge: Delivering Water-Soluble Proteins to the Ocular Surface The ocular surface is rich in a diverse array of proteins, each playing a role in
Selecting an ophthalmic formulation CRO requires a different evaluation process than selecting a general formulation provider. Ocular drug programs face challenges that are specific to
The Challenge: Frequent Intravitreal Injections Retinal disorders, including choroidal neovascularization, diabetic retinopathy, and age-related macular degeneration, can cause irreversible loss of vision. The therapeutics that
Bacterial resistance in ocular microbial disease is a recurring problem. Successive generations of antibiotic exposure establish mutations, and emergent multidrug-resistant species render existing antimicrobial treatments
Selecting a formulation development partner is a critical decision for biotech and pharmaceutical companies moving a molecule toward clinical development. The right partner can help
The Challenge: Treating Blepharitis and the Absence of Approved Ophthalmic Therapy Blepharitis is a chronic inflammation of the eyelids in which the eyelids become red,